Pep IQ
← Pep IQ
In-vitro and animal evidence from the Khavinson group at the St Petersburg Institute of Bioregulation and Gerontology spans 30+ years. Cartalax (Ala-Glu-Asp tripeptide, AED) is reported to bind specific DNA sequences in chondrocytes, modulating expression of collagen type II, proteoglycans, and matrix metalloproteinases. The bioregulator framework is unusual in Western pharmacology — short peptides claimed to enter cells and act at the gene level — and the published evidence is almost entirely from the Khavinson lab and aligned researchers.
Community protocols converge on the standard Khavinson short-course pattern: 200 mcg/day for 10 consecutive days, repeated 1–2 times per year. Some Russian protocols use higher doses (10 mg/day for 10 days) alongside conventional osteoarthritis treatment. Often stacked with other Khavinson bioregulators (Sigumir for joints, Vilon for immune). Sublingual and oral capsule formulations are sold in Russia and Eastern Europe; SubQ research vials are the Western community route.
No published Western RCTs. All efficacy claims rest on Khavinson group research, which is published but largely in Russian literature with limited Western replication. The bioregulator concept itself remains controversial in Western pharmacology — peer-reviewed mechanistic validation of the gene-level mechanism is incomplete.
Not approved as a medicine in any Western country. Sold as a dietary peptide preparation in Russia and Eastern Europe. Sourcing in Western markets is via research-peptide vendors. No serious safety signals reported in 30+ years of Russian use, but absence of large-scale RCT safety data limits confidence.
Cartalax is a long-standing Russian bioregulator with a coherent mechanistic story (chondrocyte gene regulation) and a well-established short-course protocol (200 mcg × 10 days, 1–2× yearly). But the evidence base is essentially the Khavinson group's body of work without Western RCT replication. Pep IQ flags this honestly: the protocol has 30+ years of Russian clinical practice behind it and no Western validation. Useful as a low-risk adjunct for joint health if you accept the evidence framework; not a compound where we can promise outcomes.
Cartalax belongs to a family of short peptides developed primarily by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology — the same research group behind Epitalon. The "Khavinson peptides" or "bioregulators" are a distinctive class: short sequences (typically 2-4 amino acids) that Khavinson's group proposes work by entering cells, binding to specific DNA sequences in the minor groove, and directly modulating gene expression in ageing cells. They are named and numbered (T-31, T-38, etc.) in the original Russian literature and often have trade names for supplement/research use.
Cartalax (AED — Alanine, Glutamic acid, Aspartic acid) is derived from the alpha-1 chain of type XI collagen — a structural protein found in cartilage and connective tissue. This sequence specificity gives Cartalax its proposed tissue selectivity: it is hypothesised to preferentially influence connective tissue cells — chondrocytes, fibroblasts, renal epithelial cells — because its sequence mirrors the tissue's own structural protein.
The evidence base is concentrated in Russian and Eastern European research institutions, primarily in cell culture models and limited animal studies. Almost none of this work has been independently replicated by Western institutions, and no randomised controlled trials in humans have been published. This geographic and methodological concentration is a significant limitation when evaluating the literature.
The Khavinson Literature Context: The Khavinson peptide research programme is extensive but operates in an unusual scientific context. Studies are primarily from one research group in St. Petersburg, using methodologies not always published in peer-reviewed Western journals, and the claims are extraordinarily broad for three-amino-acid compounds. This does not mean the research is invalid — Epitalon's data, for instance, has some independent support — but it warrants healthy scepticism about effect sizes and replication. Cartalax specifically has the thinnest evidence of any Khavinson peptide in current community use.
The proposed mechanism for Cartalax is structurally different from every other peptide in this book. Rather than binding cell surface receptors and triggering signalling cascades, Khavinson's group proposes that Cartalax enters cells directly and binds to specific DNA sequences in the minor groove — physically interacting with the genome to modulate gene transcription in ageing cells.
The gene expression changes reported are dramatic: 1.6-fold to 5.6-fold shifts in IGF1, FOXO1, TERT, TNKS2, and NF-κB — "resetting aging cells to a more youthful expression pattern" according to the authors. The Saint Petersburg Institute also reported a 22% increase in TERT expression in chondrocytes and 28% higher proteoglycan content in cartilage from aged rats after 60 days of treatment. These are impressive numbers — in cell cultures and one rodent study, from one research group, not independently replicated.